Evaluation of left ventricular myocardial perfusion using volumetric computed tomography with adenosine triphosphate test in patients with non-obstructive coronary artery disease during drug therapy

Aim. To study the potential of assessing left ventricular (LV) myocardial perfusion using volumetric computed tomography (VCT) with adenosine triphosphate (ATP) test in patients with non-obstructive coronary artery disease (NOCAD) during combined therapy.

Material and methods. Cardiac VCT with ATP test, combined with computed coronary angiography, was performed in 46 patients with an established diagnosis of NOCAD. At the time of enrollment, all patients were recommended lipid-lowering therapy to achieve target lipid profile parameters, antianginal and antithrombotic therapy.

Results. Changes of LV myocardial perfusion parameters depending on achievement of target low-density lipoprotein cholesterol (LDL-C) demonstrates reliable decrease in the number of LV myocardial segments with perfusion defects (2 [0; 3] vs 6 [3; 8], p<0,001) and increase in transmural perfusion coefficient (TPC) in the stress phase (1,14±0,12 vs 1,02±0,07, p=0,004). Moderate negative correlation was revealed in patients with NOCAD between the mean TPC value in the stress phase and LDL-C level (n=45, rho=-0,56; p=0,001). Significant improvement of LV myocardial perfusion was demonstrated among patients receiving combination therapy.

Conclusion. Combination therapy is significantly associated with improved LV myocardial perfusion parameters. When the target LDL-C level is reached, it is accompanied by a significant TPC increase and a decrease in the number of segments with perfusion defects in patients with NOCAD according to VCT with an ATP test.

1. Del Buono MG, Montone RA, Camilli M, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352-71. doi:10.1016/j.jacc.2021.07.042.

2. Barbarash OL, Karpov YuA, Panov AV, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Society of Cardiology. 2024;29(9):6110. (In Russ.) doi:10.15829/1560-4071-2024-6110.

3. Vrints C, Andreotti F, Koskinas KC, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-537. doi:10.1093/eurheartj/ehae177.

4. Matta A, Bouisset F, Lhermusier T, et al. Coronary Artery Spasm: New Insights. J Interv Cardiol. 2020:5894586. doi:10.1155/2020/5894586.

5. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72(23 Pt A):2841-55. doi:10.1016/j.jacc.2018.09.006.

6. Handberg EM, Merz CNB, Cooper-Dehoff RM, et al. Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021;237:90-103. doi:10.1016/j.ahj.2021.03.011.

7. Soboleva GN, Gaman SA, Ternovoy SK, et al. Clinical case: Distrurbance of myocardial perfusion in non-obstructive coronary arteries by volume computed tomography combined with adenosine triphosphate pharmacological test. Russian Electronic Journal of Radiology. 2018;8(3):273-8. (In Russ.) doi:10.21569/2222-7415-2018-8-3-273-278.

8. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.

9. Blankstein R, Shturman LD, Rogers IS, et al. Adenosine-induced stress myocardial perfusion imaging using dual-source cardiac computed tomography. J Am Coll Cardiol. 2009;54(12):1072-84. doi:10.1016/j.jacc.2009.06.014.

10. Magalhaes TA, Kishi S, George RT, et al. Combined coronary angiography and myocardial perfusion by computed tomography in the identification of flow-limiting stenosis — The CORE320 study: An integrated analysis of CT coronary angiography and myocardial perfusion. J Cardiovasc Comput Tomogr. 2015;9(5):438-45. doi:10.1016/j.jcct.2015.03.004.

11. Ezhov ME, Bliznyuk SA, Alekseeva IA, et al. Prevalence of hypercholesterolemia and statins intake in the outpatient practice in the Russian Federation (ICEBERG study) Journal of atherosclerosis and dyslipidemias. Official journal of the Russian National atherosclerosis society. 2017;4(29):5-17. (In Russ.)

12. Shalnova SA, Deev AD, Metelskaya VA, et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016;15(4):29-37. (In Russ.). doi:10.15829/1728-8800-2016-4-29-37.

13. Boiko VV, Soboleva GN, Fedorovich AA, et al. Effect of rosuvastatin on the parameters of microcirculation in patients with coronary artery disease. Russian Cardiology Bulletin. 2017;12(1):26-30. (In Russ.)

14. Ilveskoski E, Lehtimäki T, Laaksonen R, et al. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype. Scan J Clin Lab Invest. 2007;67(7):723-34. doi:10.1080/00365510701297472.

15. Wielepp P, Baller D, Gleichmann U, et al. Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease. Eur J Nucl Med Mol Imaging. 2005;32(12):1371-7. doi:10.1007/s00259-005-1828-6.

16. Sun BJ, Hwang E, Jang JY, et al. Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension. Am J Cardiol. 2014;114(8):1234-7. doi:10.1016/j.amjcard.2014.07.046.

17. Sergienko IV, Martirosyan LA. Left ventricular myocardial perfusion in patients with hypercholesterolemia during statin therapy. Atherosclerosis and dyslipidemia. 2017;2:38-47. (In Russ.)

18. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol. 2000;35(1):76-82. doi:10.1016/s0735-1097(99)00529-x.

19. Boodhwani M, Nakai Y, Voisine P, et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation. 2006; 114(1Suppl):I402-8. doi:10.1161/CIRCULATIONAHA.105.000356.

20. Indraratna P, Naoum C, Ben Zekry S, et al. Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry. RCTI. 2022;4(2):e210225. doi:10.1148/ryct.210225.